Last reviewed · How we verify
mFOLFOX6 plus cetuximab
mFOLFOX6 plus cetuximab is a chemotherapy regimen that targets cancer cells by inhibiting DNA synthesis and inducing apoptosis.
mFOLFOX6 plus cetuximab is a chemotherapy regimen that targets cancer cells by inhibiting DNA synthesis and inducing apoptosis. Used for Metastatic colorectal cancer, Advanced squamous cell carcinoma of the head and neck.
At a glance
| Generic name | mFOLFOX6 plus cetuximab |
|---|---|
| Sponsor | West China Hospital |
| Drug class | Chemotherapy regimen |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The mFOLFOX6 regimen consists of oxaliplatin, 5-fluorouracil, and leucovorin, which work together to inhibit DNA synthesis and induce apoptosis in cancer cells. Cetuximab, a monoclonal antibody, targets the epidermal growth factor receptor (EGFR), preventing it from promoting cell proliferation and survival.
Approved indications
- Metastatic colorectal cancer
- Advanced squamous cell carcinoma of the head and neck
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Neutropenia
- Anemia
Key clinical trials
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (PHASE1)
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (PHASE3)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (PHASE3)
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (PHASE1, PHASE2)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
- Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |